Source: Annual Congress 2002 - Aspects of respiratory disease in primary care
Disease area: Airway diseases

Abstract

Introduction: The UK transition strategy for CFC-based MDIs indicates the need for patient reassurance regarding the safety and effectiveness of their CFC-free (HFA) inhaler device, reinforced by written materials. In addition it recommends advice on differences in inhaler characteristics such as taste and oropharangeal impact. Methods:By postal questionnaire 1460 patients, 147 GPs and 88 PNs (response:583(40%);40(27%);23(26%)) were surveyed. Patients were asked to indicate the level of information they received at transition, including written information. In addition they were asked to compare HFA and CFC inhaler for taste and effectiveness. GPs and PNs were asked to indicate the level of information their patients had received, including provision of supplementary written information. In addition they were asked to estimate the percentage of their patients who felt their HFA inhaler a)tasted worse b)was less effective. Results: 59% of patients received sufficient information. 89% of GPs and 90% of PNs perceived their patients to have received sufficient information. 35% of patients received supplementary written materials (GP estimate, 60% and PN estimate, 100%). 19% of patients reported HFA inhaler to taste worse and 18% reported reduced effectiveness. 27.5% of GPs and 30% of PNs overestimated the level of patients reporting problems with taste. 47% of GPs and 35% of PNs overestimated patient reporting of reduced effectiveness of HFA device. Conclusion: GPs and PNs underestimated the level of information patients received but overestimated patients negative responses to inhaler characteristics. The transition strategy for other drug categories (eg inhaled steroids) should place greater emphasis on meeting patient information needs.

Rating:

Share or cite this content

Citations should be made in the following way:
M. J. Hammond, E. McShane (Liverpool, United Kingdom). A comparison of patient, general practitioner(GP) and practice nurse(PN) perception of the transition to HFA salbutamol inhalers. Eur Respir J 2002; 20: Suppl. 38, 2977

Member's Comments

No comment yet.

Related content which might interest you: How does the Novolizer fit into the choice of inhaler? Source: Annual Congress 2005 - Asthma management - important issues Year: 2005 Breath activated inhaler usage and impact on rescue medication usage in patients with an asthma diagnosis: a prescribing claims study of 2823 patients using a CFC - pMDI and a breath-actuated device Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001 Training patients on how to use metered dose inhaler (MDI) by using the 2Tone will improve asthma quality of life (AQOL) Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 The effect of face to face education about proper use of metered dose inhaler on asthma control Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Prevalence of serious post-training inhaler technique errors made by device-naïve patients using three different dry powder inhalers (DPIs) Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003 Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 The asthmatic patient and inhaler treatment devices profile in Turkey: Asthma inhaler treatment study Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 Comparing asthma and COPD inhaler devices in real life clinical practice in the UK: differences in training requirements and preference Source: International Congress 2017 – Primary care management of respiratory symptoms, allergies, inhalers and adherence Year: 2017 Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability Source: Eur Respir J 2002; 19: 246-251 Year: 2002 Patients‘ perceptions of asthma inhalers: a national (UK) survey Source: Annual Congress 2005 - Assessment and intervention from primary care centre to hospital Year: 2005 Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 A comparison between the use of aerochamber with mask and nebulized budesonide respules in young preschool children: effects on health outcome and parent satisfaction Source: Eur Respir J 2002; 20: Suppl. 38, 430s Year: 2002 Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001 Broncho dilator response to salbutamol delivered by metered dose inhaler with spacer versus dry powder inhaler in acute asthma in children Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001 Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study. Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020